Bosentan: new indication. Scleroderma and finger ulcers: no tangible efficacy.
No tangible clinical efficacy, but potentially severe adverse effects and a high potential for drug-drug interactions.
D065128:Endothelin Receptor Antagonists; D005060:Europe; D005385:Fingers / Q000473:pathology; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D011928:Raynaud Disease / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014456:Ulcer / Q000188:drug therapy*
D065128:Endothelin Receptor Antagonists; D013449:Sulfonamides